EuroBiotech: More Articles of Note


> Alizé Pharma 3 raised a €67 million ($75 million) series A round. The French biotech will use the money to move two candidates into the clinic next year. Statement (PDF)

> Johnson & Johnson returned the rights to anti-CD40 antibody ADC-1013 to Alligator Bioscience. J&J took the drug through a phase 1 trial before deciding to prioritize other assets. Release 

> A phase 3 trial of Atlantic Healthcare’s Camligo in orphan-designated pouchitis missed its co-primary endpoints. Despite the failure, Atlantic plans to meet with regulators to discuss a pathway to approval. Statement 


Overcoming Risk in Oncology Drug Development

Oncology drug development is full of potential obstacles and risks, and you must carefully plan each step. Download this whitepaper for tips on finding the fast track. Premier Research. Built for Biotech.

> Regulators on both sides of the Atlantic granted orphan drug designation to Genfit’s elafibranor in primary biliary cholangitis. Genfit plans to start a phase 3 trial in the indication later this year. Release 

> Iontas entered into an antibody optimization deal with Teva. The work will focus on antibodies against a defined target of interest to Teva. Statement 

Suggested Articles

The public financing will enable Monopar to start a phase 3 trial of a prophylactic treatment for a side effect of chemoradiotherapy. 

The dispute centers on whether Asa Abeliovich used Alector’s confidential information in connection with his work for Prevail Therapeutics.

GSK poaches Merck KGaA's Martinez-Davis to helm pharma stateside; Bulto named Novartis U.S. pharma head; Allergan's Saunders set for huge parachute.